grepcent public filings, reorganized for comparison

UNITEDHEALTH GROUP INC (UNH)

CIK: 0000731766. SIC: 6324 Hospital & Medical Service Plans. Latest 10-K as of: 2026-03-02.

SIC breadcrumb: Finance, Insurance, And Real Estate > Insurance Carriers > SIC 6324 Hospital & Medical Service Plans

SEC company page: https://www.sec.gov/edgar/browse/?CIK=731766. Latest filing source: 0000731766-26-000062.

Informational only. Descriptive public-record data — not a rating, forecast, or investment advice. See Disclaimer.

At a glance

FY2025 · period end 2025-12-31 · filed 2026-03-02 · accession 0000731766-26-000062 · source: SEC companyfacts

Revenue
447,567,000,000 USD verified
Net income
12,056,000,000 USD verified
Assets
309,581,000,000 USD verified
Free cash flow
16,075,000,000 USD computed
Net margin
2.69% computed
Operating margin
4.24% computed
Revenue YoY
+11.81% computed
ROE
12.05% computed

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

Peer groups: Managed care and health insurers · SIC 6324 Hospital & Medical Service Plans

No market price, no rating, no forecast on this site. Not investment advice.

Peer & cluster context

Peer comparisons including UNH

Peer percentile fingerprint

UNH ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC industry 6324; per-ratio N printed.UNH ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC industry 6324; per-ratio N printed.RatioUNHPeer medianPercentileNNet margin2.7%1.0%8910Operating margin4.2%1.3%10010Revenue growth11.8%12.2%3310FCF margin3.6%2.2%759ROE12.0%5.9%7810ROA3.9%2.3%8910Liabilities / equity2.082.434410Current ratio0.791.50010

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 6324 Hospital & Medical Service Plans, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

Selected Fundamentals

MetricValueUnitFYFiled
Revenue447,567,000,000USD20252026-03-02
Net income12,056,000,000USD20252026-03-02
Assets309,581,000,000USD20252026-03-02

Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-03-02. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000731766.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

Download these verified figures (annual + quarterly, with per-value filing provenance): JSON · CSV

Flow metrics use full-year FY periods from 10-K/10-K/A filings; balance-sheet metrics use FY-end instants. Free cash flow = operating cash flow - capital expenditures. Missing metrics are omitted rather than fabricated.

Metric2016201720182019202020212022202320242025
Revenue184,840,000,000201,159,000,000226,247,000,000242,155,000,000257,141,000,000287,597,000,000324,162,000,000371,622,000,000400,278,000,000447,567,000,000
Net income7,017,000,00010,558,000,00011,986,000,00013,839,000,00015,403,000,00017,285,000,00020,120,000,00022,381,000,00014,405,000,00012,056,000,000
Operating income12,930,000,00015,209,000,00017,344,000,00019,685,000,00022,405,000,00023,970,000,00028,435,000,00032,358,000,00032,287,000,00018,964,000,000
Diluted EPS7.2510.7212.1914.3316.0318.0821.1823.8615.5113.23
Operating cash flow9,795,000,00013,596,000,00015,713,000,00018,463,000,00022,174,000,00022,343,000,00026,206,000,00029,068,000,00024,204,000,00019,697,000,000
Capital expenditures1,705,000,0002,023,000,0002,063,000,0002,071,000,0002,051,000,0002,454,000,0002,802,000,0003,386,000,0003,499,000,0003,622,000,000
Dividends paid2,261,000,0002,773,000,0003,320,000,0003,932,000,0004,584,000,0005,280,000,0005,991,000,0006,761,000,0007,533,000,0007,916,000,000
Share buybacks1,280,000,0001,500,000,0004,500,000,0005,500,000,0004,250,000,0005,000,000,0007,000,000,0008,000,000,0009,000,000,0005,545,000,000
Assets122,810,000,000139,058,000,000152,221,000,000173,889,000,000197,289,000,000212,206,000,000245,705,000,000273,720,000,000298,278,000,000309,581,000,000
Liabilities82,621,000,00087,036,000,00095,994,000,000111,727,000,000126,750,000,000135,727,000,000159,358,000,000174,801,000,000195,687,000,000207,883,000,000
Stockholders' equity38,177,000,00049,833,000,00054,319,000,00060,436,000,00068,328,000,00075,045,000,00081,450,000,00094,421,000,00098,268,000,000100,090,000,000
Cash and cash equivalents10,430,000,00011,981,000,00010,866,000,00010,985,000,00016,921,000,00021,375,000,00023,365,000,00025,427,000,00025,312,000,00024,365,000,000
Free cash flow8,090,000,00011,573,000,00013,650,000,00016,392,000,00020,123,000,00019,889,000,00023,404,000,00025,682,000,00020,705,000,00016,075,000,000

Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

Metric2016201720182019202020212022202320242025
Net margin3.80%5.25%5.30%5.71%5.99%6.01%6.21%6.02%3.60%2.69%
Operating margin7.00%7.56%7.67%8.13%8.71%8.33%8.77%8.71%8.07%4.24%
Return on equity18.38%21.19%22.07%22.90%22.54%23.03%24.70%23.70%14.66%12.05%
Return on assets5.71%7.59%7.87%7.96%7.81%8.15%8.19%8.18%4.83%3.89%
Liabilities / equity2.161.751.771.851.861.811.961.851.992.08
Current ratio0.690.730.730.690.740.790.770.790.830.79

Industry Peer Context

Each number-line places UNH against the min, median, and max of latest reported values among companies in the same SIC industry when at least three peers report that ratio.

Net margin peer context

UNH Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 6324; peer count 10.UNH Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 6324; peer count 10.10 SIC peersMin -4.4%Median 1.0%Max 2.8%UNH 2.7%

Operating margin peer context

UNH Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 6324; peer count 10.UNH Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 6324; peer count 10.10 SIC peersMin -4.4%Median 1.3%Max 4.2%UNH 4.2%

ROE peer context

UNH ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 6324; peer count 10.UNH ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 6324; peer count 10.10 SIC peersMin -45.3%Median 5.9%Max 14.3%UNH 12.0%

ROA peer context

UNH ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 6324; peer count 10.UNH ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 6324; peer count 10.10 SIC peersMin -15.8%Median 2.3%Max 4.7%UNH 3.9%

Financial Bridges

Waterfall figures reconcile reported SEC companyfacts components. Missing bridges are omitted when required components are not present for the same fiscal year.

Free cash flow = operating cash flow - capital expenditures

UNH FY2025 free cash flow bridge from reported figures.UNH FY2025 free cash flow bridge from reported figures.UNH free cash flow bridgeFY2025: operating cash flow less capital expendituresSource: SEC companyfacts FY2025.Free cash flow bridgeReported amount$0.0B$10.0B$20.0B$19.7BOperating cash flow-$3.6BCapex$16.1BFree cash flow

Figure provenance: SEC companyfacts FY 2025. Operating cash flow: accession 0000731766-26-000062; concept NetCashProvidedByUsedInOperatingActivities; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities | Capital expenditures: accession 0000731766-26-000062; concept PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | Free cash flow: accession 0000731766-26-000062; concept NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

Financial Charts

UNH revenue, last 5 periods. Source: SEC companyfacts FY2025.UNH revenue, last 5 periods. Source: SEC companyfacts FY2025.UNH RevenueLatest point: FY2025 = $447.6BSource: SEC companyfacts FY2025.Fiscal yearReported revenue$0.0B$225.0B$450.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000731766-26-000062; filed 2026-03-02. Concept: Revenues. Source concepts: us-gaap:Revenues.

UNH net income, last 5 periods. Source: SEC companyfacts FY2025.UNH net income, last 5 periods. Source: SEC companyfacts FY2025.UNH Net incomeLatest point: FY2025 = $12.1BSource: SEC companyfacts FY2025.Fiscal yearNet income$0.0B$15.0B$30.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000731766-26-000062; filed 2026-03-02. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

UNH operating income, last 5 periods. Source: SEC companyfacts FY2025.UNH operating income, last 5 periods. Source: SEC companyfacts FY2025.UNH Operating incomeLatest point: FY2025 = $19.0BSource: SEC companyfacts FY2025.Fiscal yearOperating income$0.0B$20.0B$40.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000731766-26-000062; filed 2026-03-02. Concept: OperatingIncomeLoss. Source concepts: us-gaap:OperatingIncomeLoss.

UNH diluted eps, last 5 periods. Source: SEC companyfacts FY2025.UNH diluted eps, last 5 periods. Source: SEC companyfacts FY2025.UNH Diluted EPSLatest point: FY2025 = $13.23/shareSource: SEC companyfacts FY2025.Fiscal yearDiluted EPS (USD/share)$0.00/share$15.00/share$30.00/shareFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000731766-26-000062; filed 2026-03-02. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

UNH operating cash flow, last 5 periods. Source: SEC companyfacts FY2025.UNH operating cash flow, last 5 periods. Source: SEC companyfacts FY2025.UNH Operating cash flowLatest point: FY2025 = $19.7BSource: SEC companyfacts FY2025.Fiscal yearOperating cash flow$0.0B$15.0B$30.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000731766-26-000062; filed 2026-03-02. Concept: NetCashProvidedByUsedInOperatingActivities. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities.

UNH capital expenditures, last 5 periods. Source: SEC companyfacts FY2025.UNH capital expenditures, last 5 periods. Source: SEC companyfacts FY2025.UNH Capital expendituresLatest point: FY2025 = $3.6BSource: SEC companyfacts FY2025.Fiscal yearCapital expenditures$0.0B$2.0B$4.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000731766-26-000062; filed 2026-03-02. Concept: PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

UNH dividends paid, last 5 periods. Source: SEC companyfacts FY2025.UNH dividends paid, last 5 periods. Source: SEC companyfacts FY2025.UNH Dividends paidLatest point: FY2025 = $7.9BSource: SEC companyfacts FY2025.Fiscal yearDividends paid$0.0B$4.0B$8.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000731766-26-000062; filed 2026-03-02. Concept: PaymentsOfDividendsCommonStock. Source concepts: us-gaap:PaymentsOfDividendsCommonStock.

UNH share buybacks, last 5 periods. Source: SEC companyfacts FY2025.UNH share buybacks, last 5 periods. Source: SEC companyfacts FY2025.UNH Share buybacksLatest point: FY2025 = $5.5BSource: SEC companyfacts FY2025.Fiscal yearShare buybacks$0.0B$5.0B$10.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000731766-26-000062; filed 2026-03-02. Concept: PaymentsForRepurchaseOfCommonStock. Source concepts: us-gaap:PaymentsForRepurchaseOfCommonStock.

UNH assets, last 5 periods. Source: SEC companyfacts FY2025.UNH assets, last 5 periods. Source: SEC companyfacts FY2025.UNH AssetsLatest point: FY2025 = $309.6BSource: SEC companyfacts FY2025.Fiscal yearAssets$0.0B$175.0B$350.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000731766-26-000062; filed 2026-03-02. Concept: Assets. Source concepts: us-gaap:Assets.

UNH liabilities, last 5 periods. Source: SEC companyfacts FY2025.UNH liabilities, last 5 periods. Source: SEC companyfacts FY2025.UNH LiabilitiesLatest point: FY2025 = $207.9BSource: SEC companyfacts FY2025.Fiscal yearLiabilities$0.0B$125.0B$250.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000731766-26-000062; filed 2026-03-02. Concept: Liabilities. Source concepts: us-gaap:Liabilities.

UNH stockholders' equity, last 5 periods. Source: SEC companyfacts FY2025.UNH stockholders' equity, last 5 periods. Source: SEC companyfacts FY2025.UNH Stockholders' equityLatest point: FY2025 = $100.1BSource: SEC companyfacts FY2025.Fiscal yearStockholders' equity$0.0B$62.5B$125.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000731766-26-000062; filed 2026-03-02. Concept: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. Source concepts: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest.

UNH cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2025.UNH cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2025.UNH Cash and cash equivalentsLatest point: FY2025 = $24.4BSource: SEC companyfacts FY2025.Fiscal yearCash and cash equivalents$0.0B$15.0B$30.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000731766-26-000062; filed 2026-03-02. Concept: CashAndCashEquivalentsAtCarryingValue. Source concepts: us-gaap:CashAndCashEquivalentsAtCarryingValue.

UNH free cash flow, last 5 periods. Source: SEC companyfacts FY2025.UNH free cash flow, last 5 periods. Source: SEC companyfacts FY2025.UNH Free cash flowLatest point: FY2025 = $16.1BSource: SEC companyfacts FY2025.Fiscal yearFree cash flow$0.0B$15.0B$30.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000731766-26-000062; filed 2026-03-02. Concept: NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.

Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-10. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000731766.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

QuarterEnd DateRevenueNet IncomeDiluted EPSMethod
2022-Q32022-09-305.55reported discrete quarter
2023-Q12023-03-315.95reported discrete quarter
2023-Q22023-06-305.82reported discrete quarter
2023-Q32023-09-3092,361,000,0005,841,000,0006.24reported discrete quarter
2023-Q42023-12-3194,427,000,0005,455,000,000derived Q4 = FY annual - nine-month YTD
2024-Q12024-03-3199,796,000,000-1,409,000,000-1.53reported discrete quarter
2024-Q22024-06-3098,855,000,0004,216,000,0004.54reported discrete quarter
2024-Q32024-09-30100,820,000,0006,055,000,0006.51reported discrete quarter
2024-Q42024-12-31100,807,000,0005,543,000,000derived Q4 = FY annual - nine-month YTD
2025-Q12025-03-31109,575,000,0006,292,000,0006.85reported discrete quarter
2025-Q22025-06-30111,616,000,0003,406,000,0003.74reported discrete quarter
2025-Q32025-09-30113,161,000,0002,348,000,0002.59reported discrete quarter
2025-Q42025-12-31113,215,000,00010,000,000derived Q4 = FY annual - nine-month YTD
2026-Q12026-03-31111,721,000,0006,280,000,0006.90reported discrete quarter
2026-Q22026-06-30112,032,000,0005,484,000,0006.04reported discrete quarter

Quarterly Charts

UNH quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q2.UNH quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q2.UNH Quarterly RevenueLatest point: 2026-Q2 = $112.0BSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Revenue$0.0B$62.5B$125.0B2023-Q32023-Q42024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0000731766-26-000197; filed 2026-08-10. Concept: Revenues. Source concepts: us-gaap:Revenues.

UNH quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q2.UNH quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q2.UNH Quarterly Net incomeLatest point: 2026-Q2 = $5.5BSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Net income-$2.0B$0.0B$8.0B2023-Q32023-Q42024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0000731766-26-000197; filed 2026-08-10. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

UNH quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q2.UNH quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q2.UNH Quarterly Diluted EPSLatest point: 2026-Q2 = $6.04/shareSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Diluted EPS (USD/share)-$2.00/share$0.00/share$8.00/share2022-Q32023-Q12023-Q22023-Q32024-Q12024-Q22024-Q32025-Q12025-Q22025-Q32026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0000731766-26-000197; filed 2026-08-10. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

Business

Read UNH's verbatim Item 1 Business section from its latest 10-K: Business.

Risk Factors

Read UNH's verbatim Item 1A Risk Factors from its latest 10-K: Risk Factors.

Latest quarter (10-Q)

Latest 10-Q source: 0000731766-26-000197.

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Confidence: high. Filing date: 2026-08-10. Report date: 2026-06-30.

ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and Notes and with our 2025 10-K, including the Consolidated Financial Statements and Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in that report. Unless the context indicates otherwise, references to the terms “UnitedHealth Group,” the “Company,” “we,” “our” or “us” used throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations refer to UnitedHealth Group Incorporated and its consolidated subsidiaries.

Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item 2, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations expressed or implied in the forward-looking statements. A description of some of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our 2025 10-K and in the discussion below.

EXECUTIVE OVERVIEW

General

UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations we are privileged to serve.

We have four reportable segments:

•Optum Health;

•Optum Insight;

•Optum Rx; and

•UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State.

Further information on our business is presented in Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2025 10-K and additional information on our segments can be found in this Item 2 and in Note 9 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.

Net Portfolio Divestitures and Restructuring and Other Actions

Net Portfolio Divestitures

In the fourth quarter of 2025, the Company took various actions as a result of a strategic review of its assets and businesses aimed at advancing and scaling its core operations, including the value-based care business at Optum Health. For the three and six months ended June 30, 2026, these actions resulted in a net loss of $39 million and a net gain of $191 million, respectively. For the three and six months ended June 30, 2026, net portfolio divestitures included incremental losses on businesses held for sale, while the year-to-date results also included a net gain on the sales of businesses previously held for sale as of December 31, 2025. By segment, second quarter impacts consisted of net losses of $35 million and $4 million at Optum Health and Optum Insight, respectively. Year-to-date impacts consisted of gains of $524 million and $8 million at Optum Insight and Optum Rx, respectively, partially offset by a net loss of $341 million at Optum Health. Gains and losses on portfolio actions were recorded within operating costs on the Condensed Consolidated Statements of Operations.

Restructuring and Other Actions

For the three and six months ended June 30, 2026, restructuring and other actions included the net decrease in loss contract reserves of $50 million and $187 million, respectively, and net valuation gains on equity securities of $1 million and $60 million, respectively, while the year-to-date results also included a $400 million contribution to the United Health Foundation funded by the cash gain on the disposition of an Optum Insight business. By segment, the second quarter impact was $51 million at Optum Health. Year-to-date impacts were $339 million at Optum Insight, partially offset by $186 million at Optum Health. During the three months ended June 30, 2026, these items increased investment and other income by $1 million and decreased medical costs by $50 million. For the six months ended June 30, 2026, these items increased operating costs by $415 million, partially offset by a $75 million increase to investment and other income and $187 million decrease in medical costs, as reflected on the Condensed Consolidated Statements of Operations.

16

Table of Contents

Business Trends

Our businesses participate primarily in the United States health markets. We expect overall spending on health care to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being. The rate of market growth may be affected by a variety of factors, including macroeconomic conditions and regulatory changes, which could impact our results of operations, including our continued efforts to control health care costs.

Pricing Trends. To price our health care benefits, products and services, we start with our view of expected future costs, including medical care patterns, the mix and health status of people served, inflation and labor market dynamics. We continually evaluate and adjust our approach in each of the local markets we serve, considering relevant factors, such as product positioning, price competitiveness and environmental, competitive, legislative and regulatory considerations, including minimum medical loss ratio thresholds and similar revenue adjustments. We seek to balance growth and profitability across all these dimensions.

The commercial risk market remains highly competitive in the small group, large group and individual segments. We expect broad-based competition to continue as the industry adapts to individual and employer needs. Continued increased medical costs may impact both future pricing and benefit design, including for our individual exchange products, and may result in shifts between product categories for our employer benefits. These changes, along with certain regulatory impacts, have resulted in a reduction in people served and may continue in future periods. Additionally, we have voluntarily pledged to rebate 2026 profits on our individual exchange products to customers as policymakers continue to work to determine how to improve affordability in this marketplace.

Medicare Advantage funding continues to be pressured, as discussed below in “Regulatory Trends and Uncertainties,” and we have observed a continued increase in care patterns and health care unit costs as discussed below in “Medical Cost Trends,” which we have contemplated in our 2026 benefit design approach. Continued funding pressures have resulted in benefit and pricing actions, causing contraction in our Medicare Advantage membership, which we expect to continue throughout 2026.

Optum Health’s fully accountable value-based care businesses have been impacted by Medicare funding reductions and have also seen continued medical cost trend pressures, which may impact future pricing in the markets we continue to participate in. As a result of increased pricing in response to anticipated care patterns in 2026, the exit from certain markets and decreased people served through UnitedHealthcare Medicare Advantage offerings, the number of people served under value-based care arrangements has contracted and is expected to continue throughout 2026.

Due to elevated care activity in Medicaid, specifically related to behavioral, pharmacy and home health, there continues to be a timing mismatch between the health status of people served and state rate updates. The funding and payment rate environment remains insufficient to meet the health needs of patients and creates the risk of continued downward pressure on Medicaid margin percentages. We continue to take a prudent, market-sustainable posture for both new business and maintenance of existing relationships. We continue to advocate for actuarially sound rates commensurate with our medical cost trends and we remain dedicated to partnering with those states that are committed to the long-term viability of their programs. People served by Medicaid offerings declined in the first half of 2026 due to the exit from one state and reduced Medicaid eligibility.

Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, care activity and prescription drug costs. As expected and contemplated in our benefits design and pricing, we have continued to observe increased care patterns; health care unit costs; and the intensity of services delivered, which are driven by increases in provider pricing and additional services bundled per visit. Commercial medical cost trend is elevated, in part due to the independent resolution process under the No Surprises Act and more aggressive billing practice among providers. These trends may continue in future periods. We endeavor to mitigate medical cost increases by engaging hospitals, physicians and consumers with information and helping them make clinically sound choices, with the objective of helping them achieve high-quality, affordable care. Additionally, we have elevated our audit, clinical policy and payment integrity tools to protect customers and patients from unnecessary costs.

Regulatory Trends and Uncertainties

Medicare Advantage Rates. Medicare Advantage rate notices for numerous years have resulted in industry base rates well below the industry forward medical cost trend. While the Final Notice for 2027 moved towards the expected industry forward medical cost trend, it remains below. The compounding impact of multi-year rate shortfalls have created sustained pressure on the Medicare Advantage program. Further, substantial revisions to the risk adjustment model, which serves to adjust rates to reflect a patient’s health status and care resource needs, have resulted and will continue to result in reduced funding and potentially benefits for people, especially those with some of the greatest health and social challenges.

As a result of ongoing Medicare funding pressures, there are adjustments we can make to partially offset these rate pressures and reductions for a particular period. For example, we can seek to intensify our medical and operating cost management, make changes to the size and composition of our care provider networks, adjust member benefits and implement or increase the

17

Table of Contents

member premiums supplementing the monthly payments we receive from the government. Additionally, we decide annually on a county-by-county basis where we will offer Medicare Advantage plans.

SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS

The following summarizes select second quarter 2026 year-over-year operating comparisons to second quarter 2025 and other financial results.

•Consolidated revenues were consistent, with UnitedHealthcare revenues flat and Optum revenues lower by 2%.

•UnitedHealthcare served 1.6 million fewer people due to benefit design and pricing actions and reduced Medicaid eligibility and the exit from one state.

•Consolidated earnings from operations of $8.0 billion compared to $5.2 billion last year.

•Diluted earnings per common share were $6.04.

•Cash flows from operations for the six months ended June 30, 2026 were $20.0 billion.

RESULTS SUMMARY

The following table summarizes our consolidated results of operations and other financial information:

[[GREPCENT_TABLE]

[Excerpt truncated for page length; source filing is linked above.]

Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: 0000731766-26-000062. The complete FY 2025 MD&A is published at /company/UNH/mda/fy2025/.

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Confidence: high. Filing date: 2026-03-02. Report date: 2025-12-31.

ITEM 7.     MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read together with the accompanying Consolidated Financial Statements and Notes to the Consolidated Financial Statements thereto included in Part II Item 8, “Financial Statements and Supplementary Data.” Readers are cautioned the statements, estimates, projections or outlook contained in this report, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item 7, may constitute forward-looking statements within the meaning of the PSLRA. These forward-looking statements involve risks and uncertainties which may cause our actual results to differ materially from the expectations expressed or implied in the forward-looking statements. A description of some of the risks and uncertainties can be found further below in this Item 7 and in Part I, Item 1A, “Risk Factors.”

Discussions of year-over-year comparisons between 2024 and 2023 are not included in this Form 10-K and can be found in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of the Company’s Form 10-K for the fiscal year ended December 31, 2024.

EXECUTIVE OVERVIEW

General

UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations we are privileged to serve.

We have four reportable segments across our two businesses:

•Optum Health;

•Optum Insight;

•Optum Rx; and

•UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State.

Further information on our business and reportable segments is presented in Part I, Item 1, “Business” and in Note 15 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.”

2026 Business Realignment

On January 1, 2026, we realigned certain of our businesses to respond to changes in the markets we serve and the opportunities that are emerging as the health system evolves. Optum Financial, including Optum Bank, which was historically included in Optum Health, will now be included in Optum Insight. Our reportable segments will remain unchanged, with prior period segment financial information being recast to conform to the 2026 presentation, beginning with our Quarterly Report of Form 10-Q for the three months ended March 31, 2026 filed with the SEC.

Net Portfolio Divestitures, Restructuring and Other Actions and Direct Response Costs - Cyberattack

Net Portfolio Divestitures

In the fourth quarter of 2025, the Company took various actions as a result of a strategic review of the Company’s assets and businesses to operationally advance and scale core businesses and initiatives, including the value-based care business at Optum Health. These actions primarily include losses on business exits and dispositions and other businesses held for sale and a gain on the deconsolidation of a business. As a result of the Company’s portfolio actions, the Company recorded a net gain of $568 million, which included a net gain of $1.5 billion at Optum Rx, partially offset by losses of $821 million and $68 million at Optum Health and Optum Insight, respectively. Gains and losses on portfolio actions were recorded within operating costs on the Consolidated Statements of Operations.

Restructuring and Other Actions

Additionally, in the fourth quarter of 2025 the Company took restructuring and other actions that resulted in a total impact of $2.5 billion, which included real estate rationalization and workforce reductions of $746 million, contractual reassessments of $573 million, the establishment a loss contract reserve related to anticipated future losses in 2026 for certain value-based care businesses of $623 million, net valuation losses on equity securities of $329 million and the advance funding of the United Health Foundation of $250 million. The $2.5 billion impact of the restructuring and other actions was a reduction to premium revenue of $122 million and investment and other income of $397 million, and increased medical costs $623 million and operating costs $1.4 billion on the Consolidated Statements of Operations. The impacts by reportable segment were $153

25

Table of Contents

million, $1.7 billion, $236 million and $389 million, for UnitedHealthcare, Optum Health, Optum Insight and Optum Rx, respectively.

The net impact on 2026 cash flows as a result of the restructuring actions taken in 2025 is not expected to be material, with accruals recorded in 2025 resulting in operating cash outflows, offset by investing cash inflows related sales of businesses that are held for sale.

Direct Response Costs – Cyberattack

To support care providers impacted by the Change Healthcare cyberattack that occurred on February 21, 2024, the Company provided interest-free loans. In the fourth quarter of 2025, the Company increased its reserves for net collection expectations associated with provider loans and other customer balances of $799 million, which were recorded within operating costs on the Consolidated Statements of Operations and related to Optum Insight.

Business Trends

Our businesses participate primarily in the United States health markets. In the United States, health care spending has grown consistently for many years and accounted for 19% of gross domestic product (GDP) in 2025. We expect overall spending on health care to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being. The rate of market growth may be affected by a variety of factors, including macroeconomic conditions and regulatory changes, which could impact our results of operations, including our continued efforts to control health care costs.

Pricing Trends. To price our health care benefits, products and services, we start with our view of expected future costs, including medical care patterns, the mix and health status of people served, inflation and labor market dynamics. For 2025, our pricing trends and patient and member health status assumptions were well-short of the medical cost trends incurred, significantly impacting our earnings. We continually evaluate and adjust our approach in each of the local markets we serve, considering relevant factors, such as product positioning, price competitiveness and environmental, competitive, legislative and regulatory considerations, including minimum medical loss ratio (MLR) thresholds and similar revenue adjustments. We seek to balance growth and profitability across all these dimensions.

The commercial risk market remains highly competitive in the small group, large group and individual segments. We expect broad-based competition to continue as the industry adapts to individual and employer needs. Continued increased medical costs may impact both future pricing and benefit design, including for our individual exchange products in markets where we choose to remain, and may result in shifts between product categories for our employer benefits. These potential changes, along with certain regulatory impacts, may result in decreased membership in future periods.

Medicare Advantage funding continues to be pressured, as discussed below in “Regulatory Trends and Uncertainties” and we have observed increased care patterns as discussed below in “Medical Cost Trends”, which is contemplated in our 2026 benefit design approach. As a result of continued funding pressures, which have resulted in benefit and pricing actions, we expect that our Medicare Advantage membership will contract in 2026.

Optum Health’s fully accountable value-based care businesses have been impacted by Medicare funding reductions and have also seen continued medical cost trend pressures, which may impact future pricing in the markets we continue to participate in. As a result of increased pricing in response to anticipated care patterns in 2026 and decreased people served through UnitedHealthcare Medicare Advantage offerings, we expect the number of people served under value-based care arrangements to contract.

Due to elevated care activity in Medicaid, specifically related to behavioral, pharmacy and home health, there continues to be a timing mismatch between the health status of people served and state rate updates. The funding and payment rate environment remains insufficient to meet the health needs of patients and creates the risk of continued downward pressure on Medicaid margin percentages. We continue to take a prudent, market-sustainable posture for both new business and maintenance of existing relationships. We continue to advocate for actuarially sound rates commensurate with our medical cost trends and we remain dedicated to partnering with those states that are committed to the long-term viability of their programs. We expect Medicaid membership losses in 2026 as a result of reduced Medicaid eligibility and the exit from one state.

Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, care activity and prescription drug costs. We have observed increased care patterns that are above what we expected and contemplated in our pricing and benefits design. We have also observed an increase in health care unit costs and in the intensity of services delivered, driven by increases in provider pricing and additional services bundled per visit. Additionally, the member profile of newly added patients under value-based care arrangements, additional people served by our Medicare Advantage plans in markets where other plans exited, and people served within our individual exchange business have contributed to increased medical costs. These trends may continue in future periods.

26

Table of Contents

The Inflation Reduction Act (IRA) altered the Medicare Part D model and benefits, shifting more risk to plans, which results in both increased premiums and medical costs. The IRA also changed the quarterly relationship of medical costs to premiums, altering the seasonal progression and creating a more consistent relationship between medical costs and premiums throughout the year.

We endeavor to mitigate medical cost increases by engaging hospitals, physicians and consumers with information and helping them make clinically sound choices, with the objective of helping them achieve high-quality, affordable care. Additionally, we have elevated our audit, clinical policy and payment integrity tools to protect customers and patients from unnecessary costs.

Delivery System and Payment Modernization. The health care market continues to change based on demographic shifts, new regulations, political forces and both payer and patient expectations. Health plans and care providers are being called upon to work together to close gaps in care and improve overall care quality and patient experience, improve the health of populations and reduce costs. We are working to accelerate realization of these benefits through the innovation and integration of our care delivery models, including in-clinic, in-home, behavioral and virtual care, and by using our data, analytics and AI to provide clinicians with the information necessary to provide the best possible care in the most cost-efficient setting. We continue to see a greater number of people enrolled in fully accountable value-based plans that reward high-quality, affordable care and foster collaboration.

This trend is creating needs for heal

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A or browse all MD&A years.

MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

Analysis & quant

Single-company analysis

Read the cited, descriptive article for UNH: single-company analysis.

AI-assembled from public SEC filings. Verified claims: 13. Pack 760db2494573.

Macro cross-references for UNH

Indicators mapped to this company's SIC classification (industry 6324 Hospital & Medical Service Plans) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

Macro-to-micro threads including this sector: Money & trade, Government finances, Sector employment.

All 71 macro indicators →

For LLMs & downloads

Markdown twin: /company/UNH.md · JSON record: /company/UNH.json · verified financials: JSON / CSV · machine TOC for the whole site: /llms.txt